Georgina Long, BSc, PhD, MBBS, FRACP, medical oncologist, translational researcher, Melanoma Institute Australia, The University of Sydney, discusses which patients may benefit from the combination of dabrafenib and trametinib based on several recent clinical trials.
The FDA just granted a full approval of dabrafenib and trametinib for patients with unresectable or metastatic BRAF-mutated melanoma.
Researchers propose a simple prognostic score for survival that consists of 3 risk groups in patients with advanced melanoma treated with ipilimumab using readily available clinical parameters, according to a study published in the European Journal of Cancer.
The US Food and Drug Administration (FDA) has granted approval for Roche’s Cotellic (cobimetinib) in combination with Zelboraf (vemurafenib) to treat people with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma.
